Actively Recruiting
Non-ischemic Cardiomyopathy Registry, Biobank and Imaging Data Repository
Led by Montreal Heart Institute · Updated on 2025-08-13
2000
Participants Needed
1
Research Sites
365 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main goal of CaNICM is to create a central database that includes a biobank and an imaging data repository for patients with non-ischemic cardiomyopathy (NICM), as well as for at-risk family members. This includes people who carry rare genetic variants linked to NICM but do not show symptoms, and first-degree relatives. The specific goals of this database and biobank are to: Enhance investigators' ability to predict the risk of heart rhythm disorders in patients with NICM. Optimize the timing and approach for screening family members who may carry the disease - determining who to test, when, and how. Find the best ways to treat family members early to prevent or slow the disease. Future Phase - Phase 2 Goal: 4\. Prospectively evaluate how well this risk prediction model works in real-life clinical settings, and compare it to the current approach, which is often based on a single risk factor.
CONDITIONS
Official Title
Non-ischemic Cardiomyopathy Registry, Biobank and Imaging Data Repository
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Left ventricular ejection fraction (LVEF) less than 50%, and/or
- LVEF between 50% and 55% with significant late gadolinium enhancement or left ventricular dilatation, and carrying a gene variant causing non-ischemic cardiomyopathy (pathogenic or likely pathogenic in a Clingen moderate or definite gene)
You will not qualify if you...
- Significant coronary artery stenosis or history of type 1 myocardial infarction
- Significant congenital heart disease requiring intervention
- Primary valvular disease including moderate to severe aortic stenosis, moderate to severe mitral stenosis, or severe primary mitral regurgitation
- Other distinct heart diseases such as amyloid heart disease, Chagas disease, Takotsubo cardiomyopathy, sarcoidosis, hemochromatosis-related cardiomyopathy, or HIV-related cardiomyopathy
- Cardiomyopathy caused solely by substances or therapies, as judged by the cardiologist
- History of burned out hypertrophic cardiomyopathy
- Previous heart transplantation at time of first CMR
- Refusal to provide informed consent
- Patients older than 70 years at first cardiologist contact limited to 10% of total enrolled per center
- Patients with risk factors like chemotherapy or alcohol are not excluded unless these fully explain the cardiomyopathy
- Recommended to have a CMR within 3 years of inclusion
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Montreal Heart Institute
Montreal, Quebec, Canada, H1T 1C8
Actively Recruiting
Research Team
M
Melissa Lavallée
CONTACT
C
Caroline Girard
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here